We analyzed T1-weighted brain magnetic resonance imaging data of 100 cognitively normal elderly controls (NC), 127 cognitively normal Parkinson's disease (PD; PDCN) and 31 PD-associated mild cognitive impairment (PDMCI) subjects from the Norwegian ParkWest study. Using automated segmentation methods, followed by the radial distance technique and multiple linear regression we studied the effect of clinical diagnosis on hippocampal and ventricular radial distance while adjusting for age, education, and scanning site. PDCN subjects had significantly smaller bilateral hippocampal radial distance relative to NC. Nonamnestic PDMCI subjects showed smaller right hippocampal radial distance relative to NC. PDMCI subjects showed significant enlargement of all portions of the lateral ventricles relative to NC and significantly larger bilateral temporal and occipital and left frontal lateral ventricular expansion relative to PDCN subjects. Nonamnestic PDMCI subjects showed significant ventricular enlargement spanning all parts of the lateral ventricle while those with amnestic PDMCI showed changes localized to the left occipital horn. Hippocampal atrophy and lateral ventricular enlargement show promise as structural biomarkers for PD.
Introduction
Cognitive impairment, one of the most understudied nonmotor syndromes in Parkinson's disease (PD), is commonly seen even early in the disease course (Janvin et al., 2006; Muslimovic et al., 2005; Williams-Gray et al., 2009 ). PD subjects are at 2-to 6-fold increased risk for developing dementia relative to elderly controls (Breteler et al., 1995) .
Structural magnetic resonance imaging (MRI) is an increasingly recognized platform for imaging biomarker development in neurodegeneration. PD structural imaging biomarkers are significantly underdeveloped. Hippocampal atrophy, the most established imaging biomarker for Alzheimer's disease (AD), is common to most forms of dementia ), yet its presence in PD and PD dementia (PDD) has not been definitively established. While some groups have reported hippocampal atrophy in cognitively normal PD (PDCN) subjects (Bruck et al., 2004; Camicioli et al., 2003; Junqué et al., 2005; Tam et al., 2005) , others have not (Beyer et al., 2007; Burton et al., 2004; Camicioli et al., 2004; Kassubek et al., 2002; Nagano-Saito et al., 2005) . Several groups have reported structural changes of the lateral ventricles in PD (Huber et al., 1989; Meyer et al., 2007) . Meyer et al. (2007) reported that subjects with mild cognitive impairment (MCI) associated with presumed Lewy body pathology (i.e., PD or dementia with Lewy bodies) showed greater enlargement of the third ventricle relative to MCI of the Alzheimer's disease type and vascular MCI, yet similar atrophy of the medial temporal lobe structures.
Recently, we published a study investigating the hippocampal and ventricular structural changes of PD-associated mild cognitive impairment (PDMCI, disease duration 10.5 years) and PDD subjects (disease duration 13.1 years) compared with PDCN (disease duration 14.3 years) and cognitively normal elderly (NC) (Apostolova et al., 2010a) . In agreement with others (Camicioli et al., 2011) we found significant ventricular enlargement of the lateral ventricles in PDD. Yet we were unable to show significant ventricular enlargement or hippocampal atrophy in PDMCI might have been due to sample size restrictions. The goal of the present study was to investigate if ventricular enlargement is present in newly diagnosed drug-naïve PDMCI relative to newly diagnosed drug-naïve PDCN. With the larger ParkWest sample size our goal was also to more definitively address our hypothesis that PDMCI is associated with hippocampal atrophy. As PD is frequently unilateral at disease onset we repeated the regression analyses with the left-and rightpredominant PD subjects only. We also investigated the associations between hippocampal and ventricular radial distance and global cognitive (Mini-Mental State Examination [MMSE] ) and disease severity measures (Unified Parkinon's Disease Rating [UPDRS] and the modified Hoehn and Yahr [H&Y] scales).
Methods

Subjects
We analyzed the baseline structural MRI data from the Norwegian ParkWest study . ParkWest is a population-based multicenter prospective longitudinal study of newly diagnosed drug-naïve PD subjects aiming to define the clinical progression of PD over 10 years and to identify promising biomarkers for PDMCI and PDD. The protocol was reviewed and approved by the Regional Committee for Medical Research Ethics, University of Bergen, Norway.
ParkWest recruitment strategies and diagnostic procedures have been described recently . Five neurology groups from Southwestern Norway actively participated in recruitment and research evaluations of enrolled participants. Study recruitment materials were sent to all hospital departments and general practitioner offices in Southwestern Norway. Reminders were sent twice during the study recruitment period. This comprehensive surveillance/referral mechanism resulted in 604 referrals of patients with possible PD between November 1, 2004 and August 31, 2006. All subjects were evaluated by one of the 5 participating neurology groups. Only newly diagnosed drug-naïve PD patients according to the Gelb diagnostic criteria for PD (Gelb et al., 1999) were eligible for participation. ParkWest employs a multistep diagnostic procedure. Screening and baseline assessments resulted in a provisional diagnosis. Subjects then received neurological follow-up once every 6 months and at each visit the provisional diagnosis of PD was carefully reappraised. The final ParkWest study diagnosis was made on an individual basis approximately 28 months after initial enrollment according to the Gelb criteria for PD (Gelb et al., 1999) . The information used for the final study diagnosis included complete medical information from the screening and baseline research visits, as well as from the biannual clinical assessments. This included documentation of response to dopaminergic therapy and results from MRI and iodine-123-fluoropropyl-carbomethoxy-3␤-4-iodophenyltropane (FP-CIT) imaging when available. PD subjects were excluded from participation at any time during follow-up if they met criteria for the following parkinsonian disorders: dementia with Lewy bodies (DLB) according to the revised McKeith's criteria , multiple system atrophy (MSA) according to the Multiple System Atrophy consensus criteria (Gilman et al., 1998) , progressive supranuclear palsy (PSP) according to the National Institute of Neurological Disorders and the Society for PSP clinical research criteria (Litvan et al., 1996) , monosymptomatic resting tremor based on the Consensus Statement of the Movement Disorder Society on Tremor (Deuschl et al., 1998) . Subjects were also excluded if they had a history of strokes and/or stepwise progression of parkinsonism or had neuroradiologic findings of sufficient severity to be compatible with a diagnosis of "vascular parkinsonism." Others were excluded if they had parkinsonian features that developed post exposure to neuroleptics or other drugs with antagonistic properties to dopamine receptors (i.e., a diagnosis of "drug-induced parkinsonism"), or received a diagnosis of essential tremor in patients presenting with predominantly postural upper limbs or head tremor of moderate amplitude with no other signs of parkinsonism which was not caused by medication, alcohol, or hyperthyroidism.
ParkWest subjects are subjected to standardized clinical, neuropsychiatric, and neuropsychological examinations, and brain MRI. As the goal of our study was to establish structural biomarkers for PDMCI, subjects who met criteria for dementia of any cause were excluded from our analyses as previously described ). Severity of parkinsonian symptoms was assessed by the study physicians with the UPDRS (Fahn and Elton, 1987 ) and the modified H&Y staging (Hoehn and Yahr, 1967) . The neurospsychological test battery consisted of the MMSE (Folstein et al., 1975) , verbal memory assessment with the California Verbal Learning Test II (CVLT-2) (Delis et al., 1987) , assessment of visuospatial abilities with the Silhouettes and Cube subtests from the Visual Object and Space Perception Battery (VOSP) (Warrington and James, 1991) , and assessment of attention and executive functions with the semantic verbal fluency/animal naming task (Benton and Hamsher, 1989) , the Stroop Test (Stroop, 1935) and the serial 7 test from the MMSE.
Raw cognitive scores for all PD subjects were converted to z-scores using the mean and standard deviations of the ParkWest age-matched normal control (NC) group consisting of 205 individuals without parkinsonian symptoms, previous or current treatment with antiparkinsonian medication, and any disease or symptom that could preclude completion of the study-including severe physical disability. PD subjects were classified as having PDMCI if their cognitive performance on at least 1 cognitive domain (memory, visuospatial, and attention-executive) was more than 1.5 standard deviations below age-and education-adjusted NC scores yet they were independent in their activities of daily living (i.e., did not meet criteria for dementia) . Impairment in memory led to diagnosis of amnestic PDMCI, while preservation of memory with compromised nonmemory cognitive function led to diagnosis of nonamnestic PDMCI. We note that there are currently no validated measures for soliciting cognitive complaints from patients with PD. Accordingly, indication of cognitive decline based on self or informant report on IQCode and UPDRS item 1 was considered supportive of a diagnosis of MCI but was not required.
Of the 604 PD screens conducted between November 1, 2004 and August 31, 2006, 265 subjects met provisional diagnosis of incident PD. Two hundred seven drug-naïve incident PD subjects agreed to longitudinal participation. One hundred eighty-two PD and 108 NC subjects agreed to and received MRI. Of these, 258 ParkWest study participants (100 NC, 127 PDCN, 11 amnestic, and 20 nonamnestic PDMCI) had useable imaging data (i.e., no motion or significant intensity artifacts, strokes, or other structural lesions). Table 1 provides the demographic comparisons between PD subjects included in our analyses (n ϭ 158) and ParkWest PD participants who either did not agree or had contraindications to MRI, or whose scans were of insufficient quality for image analyses (n ϭ 49). PD subjects from the MRI cohort were significantly younger and more educated relative to the PD subjects without useable scans. The MRI cohort also had less cognitive and motor impairment.
MRI acquisition and preprocessing
MRI was performed at 4 of the 5 study sites. The following protocols were used: Stavanger: 1.5 T Phillips Intera (Best, The Netherlands), time to recovery (TR)/time to echo (TE) 10.0/4.6 ms, flip angle 30°, 1 mm slices with no gap, number of excitations (NEX) 2, matrix 256 ϫ 256; Haugesund: 1.5 T Phillips Intera (Best), TR/TE 20.0/4.6, flip angle 30°, 1 mm slice thickness with no gap, NEX 1, matrix 256 ϫ 256; Bergen: 1.5 T Siemens Symphony (Erlangen, Germany) TR/TE 2130.0/3.9, flip angle 15°, 1 mm slice thickness with no gap, NEX 1, matrix 256 ϫ 256; Arendal: 1.0 T Philips Intera system (Best), TR/TE 25/6.9, flip angle 30°, 2 mm slice thickness with no gap, NEX 1, matrix 256 ϫ 256.
T2-weighted and fluid attenuated inversed recovery (FLAIR) sequences were collected to evaluate subjects for strokes and/or structural lesions. Subjects with these findings or with structural changes that could produce parkinsonian symptoms were excluded from the longitudinal imaging data collection and imaging analyses. Also excluded from the imaging analyses were subjects with baseline scan artifacts or scans of insufficient quality.
The 3D T1-weighted magnetic resonance (MR) images were subjected to intensity normalization (Shattuck et al., 2001) and spatial normalization to the International Consortium for Brain Mapping (ICBM53) brain atlas using the Minctracc algorithm and 9-parameter (9P) transformation (3 translations, 3 rotations, 3 scales) (Collins et al., 1994) as previously described . The aligned images were resampled in an isotropic space of 220 voxels along each axis (x, y, and z) resulting in a final voxel size of 1 mm 3 .
Hippocampal segmentation
The hippocampal formations (including hippocampus proper, dentate gyrus, and subiculum) of a randomly selected ParkWest training data set were manually segmented on gapless coronal slices by one experienced rater (MKB) blinded to subject's age, sex, and diagnosis following a detailed well-established protocol. The traces were closely inspected for accuracy by a second experienced hippocam- pal rater (LGA). The training dataset consisted of 29 subjects with 12 subjects (4 NC, 4 PDCN, and 4 PDMCI) from each of the 2 large imaging centers (Stavanger and Bergen), 3 subjects (1 from each diagnostic group) from Arendal and 2 subjects from Haugesund (1 PDCN and 1 PDMCI). The training sample composition was proportionate to the ratio of subject enrollments among the 4 imaging centers, to prevent as far as possible any potential center bias in the statistical sampling.
Next the hippocampi of the full dataset were segmented with AdaBoost-our automated machine-learning hippocampal segmentation algorithm, based on the adaptive boosting approach. The algorithm uses thousands of voxelspecific features, such as image gradients, local curvatures at image interfaces, gray or white matter classification, statistical information on the likely stereotaxic position of the hippocampus, etc., to develop statistical rules for labeling each voxel in each new image as belonging to the hippocampus or not, based on the feature information contained in the positive and negative voxels of a training dataset. The AdaBoost algorithm has been extensively validated (Morra et al., 2008a (Morra et al., , 2010 and utilized (Apostolova et al., 2010b; Morra et al., 2008a Morra et al., , 2008b .
Ventricular segmentation
We employed a previously validated semiautomated ventricular segmentation approach (Chou et al., 2008) . Briefly, a human rater (MKB) first traced the lateral ventricles of 4 subjects and these traces were then converted into 3D parametric ventricular mesh models, termed atlases, as described in Thompson et al. (2004) . Using fluid registration techniques each atlas was separately warped to match and thereby extract the shape of the lateral ventricle of each new subject's scan. This step resulted in 4 lateral ventricle segmentations per subject that were then averaged to create 1 final ventricular model. Averaging 4 separate segmentations minimizes automated labeling errors that occur when only 1 atlas is used.
Radial distance mapping
After modeling the segmented hippocampi and lateral ventricles as 3D parametric surface meshes, we computed the medial core (a medial curve threading down the center of each structure) and the radial distance from the medial core to each surface point for each structure in each subject (Apostolova et al., 2006a (Apostolova et al., , 2006b Thompson et al., 2004) . Radial distance provides an intuitive measure of the thickness of the structure from its core to each point on its boundary.
Statistical methods
One-way analysis of variance (ANOVA) with post hoc Bonferroni correction for multiple comparisons and 2 test were used to test for between-group differences in age, sex, education, and the presence of apolipoprotein E4 (ApoE4) genotype. The presence of the ApoE4 allele was coded as 1, the absence was coded as 0. Subjects for whom ApoE4 genotype data were not available (6 NC, 9 PDCN, and 3 PDMCI representing 6%, 7%, and 10% of each group, respectively) were coded as 0.5. Due to nonnormality of distribution of the MMSE scores, between-group comparisons were conducted with the Kruskal-Wallis test when 3 groups of comparison were compared (i.e., NC, PDCN, and PDMCI) and Mann-Whitney when 2 comparison groups were compared (i.e., amnestic vs. nonamnestic PDMCI). We compared disease severity measured with the H&Y scale and the UPDRS motor subscale between PDCN and PDMCI, using a 2-tailed Student t-test.
Our main analyses were conducted with linear regression. The models included hippocampal and ventricular radial distance as the outcome and diagnosis as the predictor variable while adjusting for age, education, ApoE4 genotype, and scanning site. Linear regression models with MMSE, UPDRS motor subscale, and H&Y scores as predictors adjusting for center, and in the case of MMSE for ApoE4, were also performed in the pooled dataset. As PD is frequently unilateral at disease onset we repeated the regression analyses comparing left-and right-predominant PDCN and PDMCI subjects to the NC group. Cases with bilateral parkinsonian features were excluded from these models.
For map-wise multiple comparison correction we ran 100,000 permutations to measure the extent of the map that would have appeared significant by pure chance, in statistical maps thresholded at p Ͻ 0.01 (Thompson et al., 2003) . The final permutation corrected p-value reflects the likelihood with which the observed experimental findings would have occurred by chance alone, in null data.
Results
Demographic and cognitive between-group comparisons are shown in Tables 2 and 3, respectively. Comparing NC, PDCN, and PDMCI revealed significant between-group differences in age, education, and MMSE. After applying Bonferroni correction for multiple comparisons, we determined that the age difference was due to the PDMCI group being older than both the NC (p ϭ 0.012) and the PDCN groups (p ϭ 0.036). The difference in education was driven by a difference between the NC and PDCN groups (p ϭ 0.014). The groups were well balanced with respect to sex, disease lateralization, ApoE4 genotype, UPDRS, and H&Y scores (Table 2 ). There were significant between-group cognitive differences on all cognitive measures with the PDMCI and PDCN groups performing significantly worse than our NC group (Table 3) .
Amnestic and nonamnestic PDMCI subjects showed comparable age, sex, educational level, disease lateralization, ApoE4 genotype, UPDRS motor subscale, and MMSE distribution ( Table 2 ). The only difference seen was in H&Y scores-amnestic PDMCI subjects showed borderline sig-nificant higher scores (p ϭ 0.05). While amnestic and nonamnestic PDMCI subjects performed comparably on VOSP, serial 7, Stroop interference, and semantic fluency, amnestic MCI subjects showed significantly lower scores on CVLT and sum of words from the Stroop test (Table 3) .
Hippocampal analyses
PDCN versus NC comparisons
The PDCN versus NC 3D hippocampal radial distance statistical and percent difference maps are presented in Fig. 1 . All maps are adjusted for age, education, ApoE4 genotype, and scanning site. Compared with NC, the PDCN group had significantly smaller right hippocampal radial distance (left p corrected ϭ 0.061, right p corrected ϭ 0.0086). Quantitatively, there was a 10%-20% difference in radial distance in the areas of significance between the 2 groups ( Fig. 1 top) . In the regression analyses using left-or rightpredominant PDCN cases only (Fig. 1 bottom) we found significant differences in right hippocampal radial distance between right-predominant PDCN and NC (p corrected ϭ 0.0077). Left-predominant PDCN subjects did not show significant differences relative to NC. ApoE4 was not a significant predictor of hippocampal radial distance in any of the regression models.
PDMCI versus NC and PDCN comparisons
The PDMCI versus NC and PDMCI versus PDCN 3D hippocampal radial distance statistical and percent difference maps are presented in Fig. 2 . All maps are adjusted for age, education, ApoE4 genotype, and scanning site. While some areas in both hippocampi showed up to 30% smaller radial distance in PDMCI relative to NC, these differences did not survive stringent permutation correction for multiple comparisons. The differences in hippocampal radial distance between PDMCI and PDCN were of smaller magnitude than those seen between NC and PDMCI, and likewise did not reach statistical significance. Of the PDMCI subtypes, only the nonamnestic PDMCI group showed trendlevel smaller right hippocampal radial distance relative to NC subjects (p corrected ϭ 0.092). No trend-level or significant differences were seen between the amnestic PDMCI group and NC. Direct comparison of amnestic and nonamnestic PDMCI did not reveal significant differences in hippocampal radial distance (maps not shown). In the regression analyses using left-or right-predominant PDMCI cases only we found significant differences in right hippocampal radial distance between the right-predominant PDMCI and NC (p ϭ 0.017). Left-predominant PDMCI subjects did not show significant differences relative to NC. ApoE4 was not a significant predictor of hippocampal radial distance in any of the regression models.
MMSE, H&Y, and UPDRS associations
The center-and ApoE4-adjusted associations between hippocampal radial distance and MMSE, as well as the center-adjusted associations between hippocampal radial distance and H&Y and UPDRS motor subscale across the pooled sample can be seen in Fig. 3 . We found significant left (p corrected Ͻ 0.0001) and right (p corrected ϭ 0.00035) positive associations with MMSE. UPDRS scores similarly showed negative associations with hippocampal radial distance bilaterally (left p corrected ϭ 0.048; right p corrected ϭ 0.036), while a trend-level negative effect for H&Y was present on the right only (p corrected ϭ 0.06).
Ventricular analyses
PDCN versus NC comparisons
PDCN subjects showed no significant ventricular enlargement relative to NC.
PDMCI versus NC and PDCN comparisons
The PDMCI versus NC and PDMCI versus PDCN 3D ventricular radial distance statistical and percent difference maps are presented in Fig. 4 . All maps are adjusted for age, education, ApoE4 genotype, and scanning site. The PDMCI group showed greater left than right enlargement of the frontal, temporal, and occipital lateral ventricular horns, relative to NC (left frontal p corrected ϭ 0.0003, left temporal p corrected ϭ 0.024, left occipital p corrected ϭ 0.0003; left whole ventricle p corrected ϭ 0.0082; right frontal p corrected ϭ 0.036, right temporal p corrected ϭ 0.08, right occipital p corrected ϭ 0.036; right whole ventricle p corrected ϭ 0.047). The magnitude of between-group differences in areas of significance ranged from 5% to 25%. Splitting the PDMCI sam- Of the PDMCI subtypes, the nonamnestic PDMCI group showed extensive ventricular enlargement spanning all parts of the lateral ventricle relative to NC ranging from 5% to 25% (left frontal p corrected ϭ 0.0006, left temporal p corrected ϭ 0.03, left occipital p corrected ϭ 0.0002; left whole ventricle p corrected ϭ 0.01; right frontal p corrected ϭ 0.016, right temporal p corrected ϭ 0.056, right occipital p corrected ϭ 0.016; right whole ventricle p corrected ϭ 0.028) while amnestic PDMCI showed only a trend for ventricular enlargement of the left occipital horn relative to NC (p corrected ϭ 0.0995, % difference range: 5%-15%). Direct comparison of amnestic and nonamnestic PDMCI did not reveal significant differences in ventricular radial distance (maps not shown).
The PDMCI group showed larger bilateral temporal and occipital, and left frontal horn radial distance relative to PDCN (left frontal p corrected ϭ 0.0088, left temporal p corrected ϭ 0.022, left occipital p corrected ϭ 0.0008; left whole ventricle p corrected ϭ 0.01 right temporal p corrected ϭ 0.0094, right occipital p corrected ϭ 0.027; right whole ventricle p corrected ϭ 0.048). In this comparison the magnitude of between-group differences was 5%-20%. ApoE4 showed a trend-level association with the radial distance of the left body/occipital horn in the pooled sample only. Fig. 5 shows the center-and ApoE4-corrected significance and correlation maps between MMSE and ventricular radial distance, as well as the center-corrected significance and correlation maps between H&Y and UPDRS motor subscale scores and ventricular radial distance in the pooled sample. As expected there was a strong negative association between MMSE and the frontal (left p corrected Ͻ 0.0001; right p corrected ϭ 0.0003) and body/occipital horns (left 
MMSE, H&Y, and UPDRS associations
Discussion
Hippocampal atrophy is the most established dementia biomarker to date and occurs in Alzheimer's disease (Apostolova et al., 2006a (Apostolova et al., , 2006b (Apostolova et al., , 2010a Jack et al., 1997) , fronto-temporal (Kril and Halliday, 2004) , and vascular dementias (Xu et al., 2008) . Hippocampal atrophy in the MCI stage of Alzheimer's disease is highly predictive of future development of dementia (Apostolova et al., 2006b (Apostolova et al., , 2010a (Apostolova et al., , 2010c . While most studies to date agree that hippocampal atrophy is present in the dementia stage of PD (Bouchard et al., 2008; Camicioli et al., 2003; Junqué et al., 2005; Tam et al., 2005) , whether hippocampal atrophy is present in nondemented PD subjects has been controversial. Four studies-2 using the region of interest (ROI) approach (Camicioli et al., 2003; Junqué et al., 2005) and the other 2 a visual scale for hippocampal atrophy (Bruck et al., 2004; Tam et al., 2005) , reported hippocampal atrophy in PDCN, while 1 region of interest (Camicioli et al., 2004) and several voxel-based morphometry studies (Burton et al., 2004; Kassubek et al., 2002; Nagano-Saito et al., 2005) failed to document hippocampal atrophy in PDCN.
Here we found that hippocampal atrophy and ventricular enlargement can occur early in the course of PD and are associated with cognitive decline. We detected hippocampal atrophy not only in the PDMCI state but also in our cognitively normal PD subjects. Hippocampal atrophy in PD was strongly associated with cognitive decline and disease severity as measured by the MMSE and the UPDRS motor subscale. Postmortem data (Bertrand et al., 2004) agrees with our observation of hippocampal involvement as early as the PDCN stage. Yet more work in this area is clearly warranted. It is important to establish whether PDCN subjects with hippocampal atrophy are at increased risk for cognitive decline. Further analyses of the longitudinal ParkWest dataset will allow us to address that question. Additionally, as the subset of PDMCI subjects grows we will be able to establish the prognostic significance of hippocampal atrophy in PDMCI.
Ventricular enlargement has likewise been observed in Alzheimer's disease (Carmichael et al., 2007b; Chou and Leporé, 2010) , fronto-temporal (Kril and Halliday, 2004) , PD (Apostolova et al., 2010a) , and vascular dementias (Carmichael et al., 2007b) , and has been reported to be predictive of cognitive decline to MCI and dementia (Carmichael et al., 2007a; Chou and Leporé, 2010) . In our study we found pronounced ventricular enlargement in PDMCI but not in PDCN as we have previously reported (Dalaker et al., 2011) as well as a strong negative correlation between ventricular size and MMSE scores. Interestingly, nonamnestic PDMCI showed more pronounced ventriculomegaly relative to amnestic PD-MCI subjects with greater involvement of the posterior and frontal parts of the lateral ventricles. As nonamnestic PDMCI subjects showed deficits in the visuospatial and attention-executive domains structural changes of the parietal and frontal lobes are to be expected. The question whether ventriculomegaly precedes or coincides with the onset of the PDMCI state will be addressed as we follow our PDCN cohort longitudinally. Taking into account the wealth of reports of cortical and subcortical atrophy in PDD (Apostolova et al., 2010a; Beyer et al., 2007; Burton et al., 2004 Burton et al., , 2005 Nagano-Saito et al., 2005; Ramírez-Ruiz et al., 2005) and PDMCI (Beyer et al., 2007; Meyer et al., 2007) , one could speculate that the vetriculomegaly in PDMCI reflects cortical and subcortical involvement.
We consistently found left hemispheric involvement in our newly diagnosed drug-naïve PDMCI subjects regardless of disease laterality. Our disease lateralization analyses revealed significant contralateral ventricular and hippocampal predilection in right-predominant PDMCI subjects, but both contra-and ipsilateral ventricular enlargement in left-predominant PDMCI subjects relative to NC. One might argue that these findings potentially reflect a left-hemispheric bias in our neuropsychologic test battery, which included verbal as opposed to nonverbal memory and 2 verbal fluency tasks. However, if these right-predominant PDCN subjects convert to PDMCI and PDD at higher rates, our findings above would imply that right-sided PD poses subjects at greater risk for cognitive impairment, as has been previously suggested (Cooper et al., 2009; Williams et al., 2007) . We will be able to ascertain that when we analyze the longitudinal PDCN data. It is also worth mentioning that greater rates of lateral ventricle enlargement contralateral to the involved side has been reported by others and has been associated with faster decline in motor symptoms (Lewis et al., 2009) .
Several strengths and limitations of the present study should be acknowledged. Major strengths include the excellent recruitment and disease ascertainment strategies employed in this population-based multicenter prospective longitudinal cohort study of drug-naïve new onset PD. Advanced imaging methodology was also used for these analyses. At this time the major limitation of our analyses is that they are cross-sectional. However, as we proceed to analyses of 3-year and 5-year ParkWest structural MRI data that limitation will be overcome. Another limitation is the small sample size of the amnestic and nonamnestic PDMCI subgroups. This limitation is introduced by the study's strict inclusion criterion to enroll only newly diagnosed drug-naïve PD subjects. Such a design offers the opportunity to study PD along its longitudinal course since initial presentation, but limits our ability to have a large number of subjects meeting PD-MCI criteria. Despite this limitation the nonamnestic PDMCI was sufficiently large to detect statistically significant differences. Finally, while correcting for scanning site reduces the variability introduced by the use of different scanners and different imaging protocols as much as possible, there is no doubt some residual unmodeled variance in our data, perhaps due to scanner effects. Yet despite this noise, we were able to find significant hippocampal and ventricular differences between the diagnostic groups. Had we analyzed a dataset with a unified imaging protocol and lesser scanner variability we might have had even better power to detect disease-associated differences. 
